Abstract:Tetraploid (4N) cells are considered important in cancer because they can display increased tumorigenicity, resistance to conventional therapies, and are believed to be precursors to whole chromosome aneuploidy. It is therefore important to determine how tetraploid cancer cells arise, and how to target them. P53 is a tumor suppressor protein and key regulator of tetraploidy. As part of the "tetraploidy checkpoint", p53 inhibits tetraploid cell proliferation by promoting a G1-arrest in incipient tetraploid cells (referred to as a tetraploid G1 arrest). Nutlin-3a is a preclinical drug that stabilizes p53 by blocking the interaction between p53 and MDM2. In the current study, Nutlin-3a promoted a p53-dependent tetraploid G1 arrest in two diploid clones of the HCT116 colon cancer cell line. Both clones underwent endoreduplication after Nutlin removal, giving rise to stable tetraploid clones that showed increased resistance to ionizing radiation (IR) and cisplatin (CP)-induced apoptosis compared to their diploid precursors. These findings demonstrate that transient p53 activation by Nutlin can promote tetraploid cell formation from diploid precursors, and the resulting tetraploid cells are therapy (IR/CP) resistant. Importantly, the tetraploid clones selected after Nutlin treatment expressed approximately twice as much P53 and MDM2 mRNA as diploid precursors, expressed approximately twice as many p53-MDM2 protein complexes (by co-immunoprecipitation), and were more susceptible to p53-dependent apoptosis and growth arrest induced by Nutlin. Based on these findings, we propose that p53 plays novel roles in both the formation and targeting of tetraploid cells. Specifically, we propose that 1) transient p53 activation can promote a tetraploid-G1 arrest and, as a result, may inadvertently promote formation of therapy-resistant tetraploid cells, and 2) therapy-resistant tetraploid cells, by virtue of having higher P53 gene copy number and expressing twice as many p53-MDM2 complexes, are more sensitive to apoptosis and/or growth arrest by anti-cancer MDM2 antagonists (e.g. Nutlin).

Asymmetric clustering of centrosomes defines the early evolution of tetraploid cells

The Centrosome in Normal and Transformed Cells

Uncoordinated centrosome duplication cycle underlies the instability of non-diploid states in mammalian somatic cells

P53 Dependent Centrosome Clustering Prevents Multipolar Mitosis in Tetraploid Cells

Uncoordinated centrosome cycle underlies the instability of non-diploid somatic cells in mammals

Amplified centrosomes—more than just a threat

Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines

Genetic instability from a single S phase after whole-genome duplication

Duplication and Segregation of Centrosomes during Cell Division

Rapid proliferation of daughter cells lacking particular chromosomes due to multipolar mitosis promotes clonal evolution in colorectal cancer cells.

Tetraploid cells produced by absence of substrate adhesion during cytokinesis are limited in their proliferation and enter senescence after DNA replication

Adaptation of human cell populations to different levels of centriole amplification involves a two-step response

Novel Roles For P53 In The Genesis And Targeting Of Tetraploid Cancer Cells

Extra centrosomes delay DNA damage–driven tumorigenesis

Solving the chromosome puzzle of aneuploidy in cancer

[Correlations of Centrosome Abnormality and Genomic Instability to Tumor].

Centrioles are frequently amplified in early B cell development but dispensable for humoral immunity

Native molecular architectures of centrosomes in embryos

Centrosome Duplication and Regulation

Phylostratic Shift of Whole-Genome Duplications in Normal Mammalian Tissues towards Unicellularity Is Driven by Developmental Bivalent Genes and Reveals a Link to Cancer

Tetraploid cells from cytokinesis failure induce aneuploidy and spontaneous transformation of mouse ovarian surface epithelial cells.